Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against mycobacterial infection. We performed a comparison between the standard regimen and an alternative regimen (replacing the rifampicin of the standard regimen with clofazimine) based on the intracellular anti-MAC activities of the individual drugs in a murine model of chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC activities of the individual drugs and their combinations in murine bone marrow-derived macrophages (BMD...
ABSTRACT: Objectives: The incidence of infections due to Mycobacterium avium complex (MAC) and Myco...
Multidrug therapy is a standard practice when treating infections by nontuberculous mycobacteria (NT...
Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (D...
Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and ant...
Contains fulltext : 242637.pdf (Publisher’s version ) (Open Access)Addition of int...
BACKGROUND: Nontuberculous mycobacteria are recognized as a concern for cystic fibrosis (CF) patient...
Background/Purpose: Treatment success rates for Mycobacterium avium complex (MAC) diseases range fro...
Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) ty...
Limited data are available regarding the in vitro activity of clofazimine against nontuberculous myc...
For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cur...
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course re...
Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treat...
New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration ...
Item does not contain fulltextDisease caused by nontuberculous mycobacteria (NTM) is increasing in f...
<div><p>Treatment of Buruli ulcer, or <i>Mycobacterium ulcerans</i> disease, has shifted from surgic...
ABSTRACT: Objectives: The incidence of infections due to Mycobacterium avium complex (MAC) and Myco...
Multidrug therapy is a standard practice when treating infections by nontuberculous mycobacteria (NT...
Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (D...
Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and ant...
Contains fulltext : 242637.pdf (Publisher’s version ) (Open Access)Addition of int...
BACKGROUND: Nontuberculous mycobacteria are recognized as a concern for cystic fibrosis (CF) patient...
Background/Purpose: Treatment success rates for Mycobacterium avium complex (MAC) diseases range fro...
Patients with lung disease caused by Mycobacterium abscessus subsp. abscessus (here M. abscessus) ty...
Limited data are available regarding the in vitro activity of clofazimine against nontuberculous myc...
For Mycobacterium avium complex pulmonary disease (MAC-PD), current treatment regimens yield low cur...
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-course re...
Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treat...
New drugs and drugs with a novel mechanism of action are desperately needed to shorten the duration ...
Item does not contain fulltextDisease caused by nontuberculous mycobacteria (NTM) is increasing in f...
<div><p>Treatment of Buruli ulcer, or <i>Mycobacterium ulcerans</i> disease, has shifted from surgic...
ABSTRACT: Objectives: The incidence of infections due to Mycobacterium avium complex (MAC) and Myco...
Multidrug therapy is a standard practice when treating infections by nontuberculous mycobacteria (NT...
Drug resistance is still the major threat to global tuberculosis (TB) control, and drug-resistant (D...